Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells

4 Nov 2013

Abstract excerpt

OBJECTIVES: To compare the potency, toxicity and mechanism of action of multiple histone deacetylase inhibitors (HDACi) in activating HIV production from latency. DESIGN: In-vitro analysis of HDACi in a primary T-cell model of HIV latency and latently infected cell lines. METHODS: Latently infected chemokine ligand 19 (CCL19)-treated CD4⁺ T cells and the latently infected cell lines ACH2 and J-Lat were treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to HIV-related health complications and treatments
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24189584
DOI: 10.1097/qad.0000000000000067

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cellsPMID 24189584Read ↗

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitorsSemantic proximity Read ↗

Selective HDAC Inhibition for the Disruption of Latent HIV-1 InfectionSemantic proximity Read ↗

Therapy for Latent HIV-1 Infection: The Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for ClearanceSemantic proximity Read ↗

Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoirSemantic proximity Read ↗

The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cellsSemantic proximity Read ↗

Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency ReversalSemantic proximity Read ↗

Inhibitors of Histone DeacetylasesSemantic proximity Read ↗

A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 ExpressionSemantic proximity Read ↗

Reactivation of latent HIV by histone deacetylase inhibitorsSemantic proximity Read ↗

HIV latency: experimental systems and molecular modelsSemantic proximity Read ↗

Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV-1 latencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.